Citigroup’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-2,580
| Closed | -$47K | – | 7857 |
|
|
2020
Q4 | $47K | Buy |
2,580
+1,604
| +164% | +$29.2K | ﹤0.01% | 6090 |
|
|
2020
Q3 | $18K | Sell |
976
-1,125
| -54% | -$18.9K | ﹤0.01% | 6285 |
|
|
2020
Q2 | $31K | Sell |
2,101
-2,982
| -59% | -$42.6K | ﹤0.01% | 6307 |
|
|
2020
Q1 | $80K | Buy |
5,083
+2,657
| +110% | +$42.9K | ﹤0.01% | 5553 |
|
|
2019
Q4 | $39K | Buy |
2,426
+814
| +50% | +$13.6K | ﹤0.01% | 6522 |
|
|
2019
Q3 | $24K | Sell |
1,612
-1,698
| -51% | -$22.9K | ﹤0.01% | 6638 |
|
|
2019
Q2 | $55K | Buy |
3,310
+236
| +8% | +$3.85K | ﹤0.01% | 6395 |
|
|
2019
Q1 | $53K | Buy |
3,074
+174
| +6% | +$3.16K | ﹤0.01% | 6302 |
|
|
2018
Q4 | $51K | Sell |
2,900
-285
| -9% | -$4.84K | ﹤0.01% | 6235 |
|
|
2018
Q3 | $58K | Buy |
3,185
+1,345
| +73% | +$27.6K | ﹤0.01% | 6399 |
|
|
2018
Q2 | $36K | Buy |
+1,840
| New | +$34.5K | ﹤0.01% | 6539 |
|
|
2017
Q2 | – | Sell |
-39
| Closed | – | – | 7565 |
|
|
2017
Q1 | $0 | Sell |
39
-12,206
| -100% | -$148K | ﹤0.01% | 7411 |
|
|
2016
Q4 | $160K | Buy |
12,245
+11,251
| +1,132% | +$151K | ﹤0.01% | 5466 |
|
|
2016
Q3 | $14K | Sell |
994
-226
| -19% | -$3.21K | ﹤0.01% | 6394 |
|
|
2016
Q2 | $15K | Sell |
1,220
-6,866
| -85% | -$110K | ﹤0.01% | 6343 |
|
|
2016
Q1 | $151K | Buy |
8,086
+5,108
| +172% | +$84.7K | ﹤0.01% | 5348 |
|
|
2015
Q4 | $64K | Buy |
2,978
+2,976
| +148,800% | +$62.9K | ﹤0.01% | 5738 |
|
|
2015
Q3 | $0 | Sell |
2
-126
| -98% | -$3.13K | ﹤0.01% | 7902 |
|
|
2015
Q2 | $5K | Buy |
+128
| New | +$4.13K | ﹤0.01% | 6797 |
|
Citigroup's CBMG Position: Q1 2021 in Review
Citigroup sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 2,580 shares — an estimated $47K sold.
Citigroup first reported a position in CBMG in Q2 2015 and held it in 19 quarters. The position peaked at $160K in Q4 2016. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Citigroup reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Citigroup sold 2,580 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $47K.
- Citigroup first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 19 quarters.
- Citigroup's Cellular Biomedicine Group, Inc. position peaked at $160K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.